1. Pharmacological basis and clinical evidence of dabigatran therapy
- Author
-
Maria-Paz Martínez, Teresa Tejerina, Jorge Navarro-Dorado, Marta Ramajo, Santiago Redondo, and Abelardo Barez
- Subjects
medicine.medical_specialty ,Cancer Research ,Disease ,Review ,lcsh:RC254-282 ,Dabigatran ,surgery ,medicine ,Chronic atrial fibrillation ,media_common.cataloged_instance ,Humans ,dabigatran ,atrial fibrillation ,European union ,Intensive care medicine ,Stroke ,Molecular Biology ,thrombosis ,media_common ,business.industry ,lcsh:RC633-647.5 ,Anticoagulants ,Atrial fibrillation ,Hematology ,lcsh:Diseases of the blood and blood-forming organs ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Thrombosis ,Oncology ,Clinical evidence ,beta-Alanine ,Kidney Failure, Chronic ,Benzimidazoles ,business ,medicine.drug - Abstract
Dabigatran is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity. It has been approved in the European Union and the United States of America for the prevention of thrombosis after major orthopedic surgery. It has also been approved by the American Food and Drug Administration and the European Medicines Agency for the prevention of stroke in chronic atrial fibrillation. Dabigatran provides a stable anticoagulation effect without any need to perform periodical laboratory controls. Of note, there is a growing amount of clinical evidence which shows its safety and efficacy. For these reasons, dabigatran may suppose a revolution in oral anticoagulation. However, two important limitations remain. First, it is contraindicated in patients with end-stage renal disease. Second, there is no evidence of the prevention of thrombosis in mechanical heart valves.
- Published
- 2011